News and Trends 18 Jun 2019
Dutch Biotech Boosts Hepatitis B Vaccine Effectiveness
Phase II results from Dutch biotech CyTuVax show its enhanced hepatitis B vaccine reduces non-responders by 13%. Around 15% of people receiving vaccines for hepatitis B fail to produce antibodies that protect them against the infection. These non-responders are often given more injections of the vaccine in an attempt to trigger the immune system, but […]